FDA ICH Q&A Webinar Registration Now Open!
October 15 -16, 2020. This webinar will feature presentations & discussion from the ICH E14/S7B Implementation Working Group on the Draft Q&As. Learn more and Register online here.
The objective of the CIPA initiative is to facilitate the adoption of a new paradigm for assessment of clinical potential of TdP that is not measured exclusively by potency of hERG block and not at all by QT prolongation.
The CiPA Steering Team does not offer any formal endorsement or certifications at this time. Read the disclaimer.